ArticleBMC health services research2003
The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis.
Article in BMC health services research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 42 citations in OpenAlex.
- Printed educational messages fail to increase use of thiazides as first-line medication for hypertension in primary care: a cluster randomized controlled trial [ISRCTN72772651].Implementation science : IS · 2016Trial
- A theory-based process evaluation alongside a randomised controlled trial of printed educational messages to increase primary care physicians' prescription of thiazide diuretics for hypertension [ISRCTN72772651].Implementation science : IS · 2016Trial
- Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention.PLoS medicine · 2006Trial
- Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: A population-based study.Journal of clinical hypertension (Greenwich, Conn.) · 2017Article
- Economic evaluation for first-line anti-hypertensive medicines: applications for the Philippines.Cost effectiveness and resource allocation : C/E · 2012Article
- Physician adherence to hypertension treatment guidelines and drug acquisition costs of antihypertensive drugs at the cardiac clinic: a pilot study.Patient preference and adherence · 2012Article
- Management of hypertension at the community level in sub-Saharan Africa (SSA): towards a rational use of available resources.Journal of human hypertension · 2011Article
- Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations.PharmacoEconomics · 2009Review
- Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan.BMC health services research · 2008Article
- Cost-effectiveness analysis of guidelines for antihypertensive care in Finland.BMC health services research · 2007Article
- Evaluation of thiazide diuretic use as preferred therapy in uncomplicated essential hypertension patients.Pharmacy practice · 2007Article
- The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis.PLoS medicine · 2007Article
- International variation in prescribing antihypertensive drugs: its extent and possible explanations.BMC health services research · 2005Article
- Back to thiazide-diuretics for hypertension: reflections after a decade of irrational prescribing.BMC family practice · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAll clinical practice guidelines recommend thiazides as a first-choice drug for the management of uncomplicated hypertension. Thiazides are also the lowest priced antihypertensive drugs. Despite this, the use of thiazides is much lower than that of other drug-classes. We wanted to estimate the potential for savings if thiazides were used as the first choice drug for the management of uncomplicated hypertension.
methodsFor six countries (Canada, France, Germany, Norway, the UK and the US) we estimated the number of people that are being treated for hypertension, and the proportion of them that are suitable candidates for thiazide-therapy. By comparing this estimate with thiazide prescribing, we calculated the number of people that could switch from more expensive medication to thiazides. This enabled us to estimate the potential drug-cost savings. The analysis was based on findings from epidemiological studies and drug trials, and data on sales and prescribing provided by IMS for the year 2000.
resultsFor Canada, France, Germany, Norway, the UK and the US the estimated potential annual savings were US13.8 million dollars, US37.4 million dollars, US72.2 million dollars, US10.7 million dollars, US119.7 million dollars and US433.6 million dollars, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.